Tourmaline Bio, Inc.
TRML evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Lead Asset:
- pacibekitug (Phase 2)
What it means
What to watch
Prepared research question
What matters most for TRML—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
pacibekitug (Phase 2)
Next Catalyst
—
Tracking 2 pipeline candidates · 1 clinical trial for Tourmaline Bio, Inc..
Run Tourmaline Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tourmaline Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is Tourmaline Bio, Inc.'s lead drug candidate?
Tourmaline Bio, Inc.'s most advanced tracked candidate is pacibekitug (Phase 2) for Thyroid eye disease (TED).
Who is the CEO of Tourmaline Bio, Inc.?
Sandeep Kulkarni, M.D. is the chief executive officer of Tourmaline Bio, Inc. (TRML).
What therapeutic areas does Tourmaline Bio, Inc. focus on?
Tourmaline Bio, Inc. develops therapies across Ophthalmology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.